Glenmark’s branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA
Mumbai, India, December 19, 2018: Glenmark Pharmaceuticals, a research-led global integrated pharmaceutical company, today
announced its foray into the branded dermatology segment in the United States. The branded portfolio for the US market will be
developed and commercialized by Glenmark Therapeutics Inc., USA, which is a wholly owned subsidiary of Glenmark Holding, SA. This represents an important step in the company’s long-term strategy to build a robust branded business in the US, alongside the company’s existing and successful generics business.
In support of this new business, Glenmark Therapeutics recently acquired the rights to seven branded dermatology products from
Exeltis USA, Inc. The acquisition includes Ecoza® (econazole nitrate) topical foam, 1%, an anti-fungal medicine indicated for the
treatment of interdigital tinea pedis or athlete’s foot, and Recede® topical gel, a leading prescription product for scar management. The cumulative sales of the seven acquired brands were USD 9 million. All the acquired products are currently approved and marketed in the US, giving Glenmark Therapeutics an immediate entry into the topical branded products segment. In addition, Glenmark Therapeutics intends to launch other branded dermatology products over the next 12 months.
“Glenmark Pharmaceuticals has been committed to the area of dermatology globally for more than two decades. With our
significant presence in the generic dermatology market in the US, this acquisition will give us a leading edge as we enter into a
new segment of branded products. It will also serve as the foundation for commercialization of future branded assets in the US,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. “We see strong growth potential in the branded segment, particularly with the kind of products we have acquired and the products we have in our own pipeline in the areas of dermatology and respiratory. With our strategic focus on moving up the value chain, we remain optimistic that these franchises will catalyze the growth trajectory of our US business,” said Robert Matsuk, President– North America and Global API, Glenmark Pharmaceuticals. Glenmark Therapeutics’ acquisition also includes the Exeltis dermatology field force, which manages well-established relationships with healthcare professionals. Glenmark plans to have a field force of about 30 sales representatives for the branded division.
According to IQVIA sales data for the 12-month period ending October 2018, the topical branded dermatology products market in the US is estimated to be valued at USD 1.9 billion and has been growing at a CAGR of 6.6% over the last five years.